These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33676886)

  • 21. A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol.
    Bhat Y; Dixit A; Mistri A; Patel B; Quoraishi SH; Uprichard J
    BMC Neurol; 2019 Nov; 19(1):306. PubMed ID: 31783738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial rivaroxaban dosing in patients with atrial fibrillation.
    Ablefoni K; Buchholz A; Ueberham L; Hilbert S; Dagres N; Husser D; Hindricks G; Bollmann A
    Clin Cardiol; 2019 Oct; 42(10):873-880. PubMed ID: 31317562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
    Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
    Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
    Leef GC; Hellkamp AS; Patel MR; Becker RC; Berkowitz SD; Breithardt G; Halperin JL; Hankey GJ; Hacke W; Nessel CC; Singer DE; Fox KAA; Mahaffey KW; Piccini JP
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28615214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation.
    Jackevicius CA; Tsadok MA; Essebag V; Atzema C; Eisenberg MJ; Tu JV; Lu L; Rahme E; Ho PM; Turakhia M; Humphries KH; Behlouli H; Zhou L; Pilote L
    Heart; 2017 Sep; 103(17):1331-1338. PubMed ID: 28286333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
    Washam JB; Hellkamp AS; Lokhnygina Y; Piccini JP; Berkowitz SD; Nessel CC; Becker RC; Breithardt G; Fox KAA; Halperin JL; Hankey GJ; Mahaffey KW; Singer DE; Patel MR;
    Am J Cardiol; 2017 Aug; 120(4):588-594. PubMed ID: 28645473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and outcomes of Japanese atrial fibrillation patients with poor medication adherence: A sub-analysis of the GENERAL study.
    Akao M; Tsuji H; Kusano K; Matsui K; Hiramitsu S; Hatori Y; Odakura H; Ogawa H
    J Cardiol; 2023 Feb; 81(2):209-214. PubMed ID: 35985869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights Into Direct Oral Anticoagulant Therapy Implementation of Stroke Survivors with Atrial Fibrillation in an Ambulatory Setting.
    Albert V; Polymeris AA; Dietrich F; Engelter ST; Hersberger KE; Schaedelin S; Lyrer PA; Arnet I
    J Stroke Cerebrovasc Dis; 2021 Feb; 30(2):105530. PubMed ID: 33333334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study.
    Evans A; Davies M; Osborne V; Roy D; Shakir S
    PLoS One; 2020; 15(10):e0240489. PubMed ID: 33035259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation.
    Perreault S; de Denus S; White-Guay B; Côté R; Schnitzer ME; Dubé MP; Dorais M; Tardif JC
    Pharmacotherapy; 2020 Jan; 40(1):40-54. PubMed ID: 31758592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.
    Laube ES; Yu A; Gupta D; Miao Y; Samedy P; Wills J; Harnicar S; Soff GA; Mantha S
    Am J Cardiol; 2017 Jul; 120(2):213-217. PubMed ID: 28549819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
    Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
    Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study.
    Althunian TA; de Boer A; Groenwold RHH; Rengerink KO; Souverein PC; Klungel OH
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1263-1272. PubMed ID: 32537897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.